No effect of the prothrombin G20210A mutation on protein C activation in a large kindred with type I protein C deficiency

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 7, 2004, Pages 573-576

  Vossen, Carla Y ^a,c   Strandberg, Karin ^d   Stenflo, Johan ^d   Rosendaal, Frits R ^c   Callas, Peter W ^b   Long, George L ^a   Bovill, Edwin G ^a  

^a UNIVERSITY OF VERMONT   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Activated protein C protein C inhibitor; Protein C deficiency; Prothrombin G20210A mutation

Indexed keywords

ACTIVATED PROTEIN C; ADENINE; FIBRINOPEPTIDE A; GUANINE; PLASMINOGEN ACTIVATOR INHIBITOR 3; PROTEIN C; PROTHROMBIN; THROMBIN;

ARTICLE; BLOOD SAMPLING; CANADA; COMPLEX FORMATION; EVALUATION; GENE INSERTION; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN C DEFICIENCY; PROTEIN FUNCTION; TYPE 1 PROTEIN C DEFICIENCY;

BLOOD COAGULATION TESTS; FEMALE; HUMANS; MALE; MUTATION; PROTEIN C; PROTEIN C DEFICIENCY; PROTEIN C INHIBITOR; PROTHROMBIN;

EID: 5644250480     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200409000-00007     Document Type: Article

References (31)

1. Griffin JH, Evatt B, Zimmerman TS, Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68:1370-1373.
2. Miletich J, Sherman L, Broze G, Jr. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317:991-996.
3. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood 1989; 73:712-717.
4. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341:134-138.
5. Bertina RM, Broekmans AW, van der Linden IK, Mertens K. Protein C deficiency in a Dutch family with thrombotic disease. Thromb Haemost 1982; 48:1-5.
6. Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81:198-202.
7. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84:1031-1035.
8. Makris M, Preston FE, Beauchamp NJ, Cooper PC, Daly ME, Hampton KK, et al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost 1997; 78:1426-1429.
9. Hasstedt SJ, Bovill EG, Callas PW, Long GL. An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. Am J Hum Genet 1998; 63:569-576.
10. Bovill EG, Hasstedt SJ, Callas PW, Valliere JE, Scott BT, Bauer KA, Long GL. The G20210A prothrombin polymorphism is not associated with increased thromboembolic risk in a large protein C deficient kindred. Thromb Haemost 2000; 83:366-370.
11. Bovill EG, Bauer KA, Callas PW, Valliere JE, Scott BT, Long GL. Prothrombin concentration has a positive correlation with thrombin generation but, a seemingly paradoxical, negative correlation with protein C activation in a large protein C deficient kindred [Abstract]. Thromb Haemost 1999; 82:216a.
12. Bauer KA, Humphries S, Smillie B, Li L, Cooper JA, Barzegar S, et al. Prothrombin activation is increased among asymptomatic carriers of the prothrombin G20210A and factor V Arg506Gln mutations. Thromb Haemost 2000; 84:396-400.
13. Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983; 258:163-168.
14. Suzuki K. Activated protein C inhibitor. Semin Thromb Hemost 1984;10:154-161.
15. Strandberg K, Kjellberg M, Knebel R, Lilja H, Stenflo J. A sensitive immunochemical assay for measuring the concentration of the activated protein C-protein C inhibitor complex in plasma: use of a catcher antibody specific for the complexed/cleaved form of the inhibitor. Thromb Haemost 2001; 86:604-610.
16. Sala N, Owen WG, Collen D. A functional assay of protein C in human plasma. Blood 1984; 63:671-675.
17. Tomczak JA, Ando RA, Sobel HG, Bovill EG, Long GL. Genetic analysis of a large kindred exhibiting type I protein C deficiency and associated thrombosis. Thromb Res 1994; 74:243-254.
18. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88:3698-3703.
19. Strandberg K, Astermark J, Björgell O, Becker C, Nilsson PE, Stenflo J. Complexes between activated protein C and protein C inhibitor measured with a new method: comparison of performance with other markers of hypercoagulability in the diagnosis of deep vein thrombosis. Thromb Haemost 2001; 86:1400-1408.
20. Strandberg K, Svensson A, Stenflo J. Stabilyte tubes that contain strongly acidic citrate prevent in vitro complex formation between activated protein C and protein C inhibitor. Thromb Haemost 2003; 89:947-949.
21. Zar JH. Biostatistical analysis, 4th edition. Upper Saddle River, NJ: Prentice Hall; 1999.
22. Vossen CY, Hasstedt SJ, Rosendaal FR, Callas PW, Bauer KA, Broze GJ et al. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost 2004; 2:242-247.
23. Hillarp A, Zoller B, Svensson PJ, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997; 78:990-992.
24. Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Férec C, Mottier D. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998; 80:49-51.
25. Margaglione M, Brancaccio V, Giuliani N, D'Andrea G, Cappucci G, Iannaccone L, et al. Increased risk for venous thrombosis in carriers of the prothrombin G → A20210 gene variant. Ann Intern Med 1998; 129:89-93.
26. Simioni P, Tormene D, Manfrin D, Gavasso S, Luni S, Stocco D, Girolami A. Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br J Haematol 1998; 103:1045-1050.
27. Kyrle PA, Mannhalter C, Béguin S, Stümpflen A, Hirschl M, Weltermann A, et al. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18:1287-1291.
28. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79:2340-2348.
29. Hockin MF, Kalafatis M, Cawthern KM, Simioni P, Mann KG. A thrombin mediated endothelial cell dependent mechanism for factor Va inactivation [Abstract]. Blood 1998; 92:183a.
30. Smirnov MD, Safa O, Esmon NL, Esmon CT. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood 1999; 94:3839-3846.
31. Åstrup T. The haemostatic balance. Thromb Diath Haemorrh (Stutt) 1958; 2:347-357.